Full Text:   <620>

Summary:  <49>

Suppl. Mater.: 

CLC number: 

On-line Access: 2024-12-30

Received: 2023-10-30

Revision Accepted: 2024-04-24

Crosschecked: 2024-12-30

Cited: 0

Clicked: 1272

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Xiaoming FENG

https://orcid.org/0009-0004-3663-2787

Yuyuan MA

https://orcid.org/0000-0001-7193-6023

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2024 Vol.25 No.12 P.1108-1114

http://doi.org/10.1631/jzus.B2300790


Olig2+ single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model


Author(s):  Deqing PENG, Ruijie LU, Leyao L, Qing YAO, Kaichuang YANG, Yunfeng XU, Xiaoming FENG, Ruolang PAN, Yuyuan MA

Affiliation(s):  Center for Rehabilitation Medicine, Department of Neurosurgery, Zhejiang Provincial Peoples Hospital (Affiliated Peoples Hospital, Hangzhou Medical College),Hangzhou310014,China; more

Corresponding email(s):   fengxiaoming2022@163.com, yuyuan_ma98246@163.com

Key Words:  Cranial bone marrow, Single colony, Mesenchymal stem cells, Oligodendrocytes, Demyelination


Deqing PENG, Ruijie LU, Leyao L, Qing YAO, Kaichuang YANG, Yunfeng XU, Xiaoming FENG, Ruolang PAN, Yuyuan MA. Olig2+ single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model[J]. Journal of Zhejiang University Science B, 2024, 25(12): 1108-1114.

@article{title="Olig2+ single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model",
author="Deqing PENG, Ruijie LU, Leyao L, Qing YAO, Kaichuang YANG, Yunfeng XU, Xiaoming FENG, Ruolang PAN, Yuyuan MA",
journal="Journal of Zhejiang University Science B",
volume="25",
number="12",
pages="1108-1114",
year="2024",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300790"
}

%0 Journal Article
%T Olig2+ single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model
%A Deqing PENG
%A Ruijie LU
%A Leyao L
%A Qing YAO
%A Kaichuang YANG
%A Yunfeng XU
%A Xiaoming FENG
%A Ruolang PAN
%A Yuyuan MA
%J Journal of Zhejiang University SCIENCE B
%V 25
%N 12
%P 1108-1114
%@ 1673-1581
%D 2024
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300790

TY - JOUR
T1 - Olig2+ single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model
A1 - Deqing PENG
A1 - Ruijie LU
A1 - Leyao L
A1 - Qing YAO
A1 - Kaichuang YANG
A1 - Yunfeng XU
A1 - Xiaoming FENG
A1 - Ruolang PAN
A1 - Yuyuan MA
J0 - Journal of Zhejiang University Science B
VL - 25
IS - 12
SP - 1108
EP - 1114
%@ 1673-1581
Y1 - 2024
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300790


Abstract: 
oligodendrocytes are the myelinating cells of the central nervous system. Brain injury and neurodegenerative disease often lead to oligodendrocyte death and subsequent demyelination-related pathological changes, resulting in neurological defects and cognitive impairment (Spaas et al., 2021; Zhang J et al., 2022). Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system. The pathology of MS is characterized by the loss of myelin, oligodendrocytes, and axons in the brain, brain stem, and spinal cord, as well as by white matter lesions (Lassmann et al., 2007). Unfortunately, no definitive cure for MS has been developed. Immunomodulatory and anti-inflammatory drugs are effective in the relapsing-remitting phase of MS because they reduce the frequency of relapses and the formation of inflammatory lesions; however, they do not alter the course of progressive MS and are insufficient to cure chronic neurological dysfunction (Xiao et al., 2015; Zhang et al., 2021). The treatment outcome is even worse for MS patients with primary and secondary progressions. mesenchymal stem cells (MSCs) are stromal cells that can self-renew and exhibit multilineage differentiation. MSCs are easy to expand in vitro and exhibit low immunogenicity, no tumorigenic risks, and ethical controversies, making them a promising candidate for regenerative medicine (Zhang L et al., 2022; Xu et al., 2023). Many studies have confirmed the neural differentiation potential of MSCs under certain conditions, making them a prime candidate for treating neurodegenerative diseases (Jang et al., 2010; Yan et al., 2013). The present study investigated the effects of cranial bone-marrow mesenchymal stem cells (cBMMSCs) and oligodendrocyte-specific protein 2-positive (Olig2+) single-colony-derived cBMMSC (sc-cBMMSC), isolated in our previous work (Yang et al., 2022), in a central nervous system demyelination mouse model.

Olig2+单克隆颅骨间充质干细胞在双环己酮草酰二腙(CPZ)诱导的小鼠脱髓鞘模型中促再生作用研究

彭德清1, 卢睿杰2, 吕乐瑶2, 姚情3, 杨开创1, 徐云峰4, 冯小明4, 潘若浪5, 麻育源1
1浙江省人民医院(杭州医学院附属人民医院)康复中心, 神经外科, 中国杭州市, 310014
2温州医科大学附属第二临床医学院, 中国温州市, 325035
3温州医科大学药学院, 中国温州市, 325035
4嘉兴市第一医院(嘉兴大学附属医院)神经外科, 中国嘉兴市, 314001
5浙江省细胞药物与应用技术研究重点实验室, 中国杭州市, 311122
摘要:多发性硬化症是中枢神经系统的主要脱髓鞘疾病,目前尚无有效治疗方法。本研究探讨了颅骨间充质干细胞(cBMMSC)和Olig2+单克隆来源cBMMSC(sc-cBMMSC)在双环己酮草酰二腙(CPZ)诱导的中枢神经系统脱髓鞘小鼠模型中的作用。通过尾静脉输注cBMMSC和Olig2+ sc-cBMMSC,剂量为1×106个细胞每100微升磷酸盐缓冲液(PBS),每周一次,给药两周。治疗完成一周后,对每组小鼠进行相关指标评估。结果表明,cBMMSC移植可显著提高CPZ诱导的脱髓鞘小鼠在转棒、悬挂和水迷宫试验中的能力;抑制小鼠外周血和中枢神经系统中TNF-α、IL-1β和IL-6等炎症因子的水平;此外,小鼠病理结构也得到改善,具体表现在髓鞘得到显著恢复,以及Olig2和Syn表达增加。值得注意的是,与cBMMSC相比,Olig2+ sc-cBMMSC更为显著地改善了CPZ动物的行为学、髓鞘修复和神经细胞再生。这些发现表明,颅骨髓来源的干细胞在脱髓鞘中具有修复作用,这可能归因于其对少突胶质细胞的免疫调节和保护。Olig2+ sc-cBMMSC移植效果更为显著,进一步证实了间充质干细胞的异质性应被考虑和利用以提高对特定疾病的治疗效果。

关键词:颅骨骨髓;单克隆;间充质干细胞;少突胶质细胞;脱髓鞘

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]AllegrettaC,D'AmicoE,ManutiV,et al.,2022.Mesenchymal stem cell-derived extracellular vesicles and their therapeutic use in central nervous system demyelinating disorders.Int J Mol Sci,23(7):3829.

[2]AvşarT,ErdemGÇ,TerzioğluG,et al.,2021.Investigation of neuro-inflammatory parameters in a cuprizone induced mouse model of multiple sclerosis.Turk J Biol,45(5):‍644-655.

[3]BiglariN,MehdizadehA,Vafaei MastanabadM,et al.,2023.Application of mesenchymal stem cells (MSCs) in neurodegenerative disorders: history, findings, and prospective challenges.Pathol Res Pract,247:154541.

[4]ConnerLT,SrinageshwarB,BakkeJL,et al.,2023.Advances in stem cell and other therapies for Huntington’s disease: an update.Brain Res Bull,199:110673.

[5]EldalyAS,MashalySM,FoudaE,et al.,2022.Systemic anti-inflammatory effects of mesenchymal stem cells in burn: a systematic review of animal studies.J Clin Transl Res,8(4):276-291.

[6]el SharounySH,ShaabanMH,ElsayedRM,et al.,2022.N-acetylcysteine protects against cuprizone-induced demyelination: histological and immunohistochemical study.Folia Morphol (Warsz),81(2):280-293.

[7]HedayatpourA,RagerdiI,PasbakhshP,et al.,2013.Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis.Cell J,15(2):142-151.

[8]IslamMA,AlamSS,KunduS,et al.,2023.Mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis.J Clin Med,12(19):6311.

[9]JangS,ChoHH,ChoYB,et al.,2010.Functional neural differentiation of human adipose tissue-derived stem cells using bFGF and forskolin.BMC Cell Biol,11:25.

[10]KandeelM,MorsyMA,AlkhodairKM,et al.,2023.Mesenchymal stem cell-derived extracellular vesicles: an emerging diagnostic and therapeutic biomolecules for neurodegenerative disabilities.Biomolecules,13(8):1250.

[11]KashaniIR,HedayatpourA,PasbakhshP,et al.,2015.Progesterone enhanced remyelination in the mouse corpus callosum after cuprizone induced demyelination.Iran J Med Sci,40(6):507-514.

[12]KashaniSA,NavabiR,AminiA,et al.,2023.Immunomodulatory potential of human clonal mesenchymal stem cells and their extracellular vesicle subpopulations in an inflammatory-mediated diabetic rhesus monkey model.Life Sci,329:121950.

[13]LassmannH,BrückW,LucchinettiCF,2007.The immunopathology of multiple sclerosis: an overview.Brain Pathol,17(2):210-218.

[14]LyaminaS,BaranovskiiD,KozhevnikovaE,et al.,2023.Mesenchymal stromal cells as a driver of inflammaging.Int J Mol Sci,24(7):6372.

[15]MoQY,ZhangW,ZhuAJ,et al.,2022.Regulation of osteogenic differentiation by the pro-inflammatory cytokines IL-‍1β and TNF-α: current conclusions and controversies.Hum Cell,35(4):957-971.

[16]SoltiI,KvellK,TalaberG,et al.,2015.Thymic atrophy and apoptosis of CD4+CD8+ thymocytes in the cuprizone model of multiple sclerosis.PLoS ONE,10(6):e0129217.

[17]SpaasJ,van VeggelL,SchepersM,et al.,2021.Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders.Cell Mol Life Sci,78(10):4615-4637.

[18]VassallKA,BammVV,HarauzG,2015.Myelstones: the executive roles of myelin basic protein in myelin assembly and destabilization in multiple sclerosis.Biochem J,472(1):17-32.

[19]XiaoJ,YangRB,BiswasS,et al.,2015.Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.Int J Mol Sci,16(5):9283-9302.

[20]XuYZ,FanP,LiuL,et al.,2023.Novel perspective in transplantation therapy of mesenchymal stem cells: targeting the ferroptosis pathway.J Zhejiang Univ-Sci B (Biomed & Biotechnol),24(2):115-129.

[21]YanZJ,HuYQ,ZhangHT,et al.,2013.Comparison of the neural differentiation potential of human mesenchymal stem cells from amniotic fluid and adult bone marrow.Cell Mol Neurobiol,33(4):465-475.

[22]YangKC,LuRJ,LuJN,et al.,2022.Phenotypic and functional characterizations of mesenchymal stem/stromal cells isolated from human cranial bone marrow.Front Neurosci,16:909256.

[23]ZhangJ,BullerBA,ZhangZG,et al.,2022.Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system.Exp Neurol,347:113895.

[24]ZhangL,LiY,DongYC,et al.,2022.Transplantation of umbilical cord-derived mesenchymal stem cells promotes the recovery of thin endometrium in rats.Sci Rep,12:412.

[25]ZhangRB,LiuJ,XuB,et al.,2021.Cornuside alleviates experimental autoimmune encephalomyelitis by inhibiting Th17 cell infiltration into the central nervous system.J Zhejiang Univ-Sci B (Biomed & Biotechnol),22(5):‍421-430.

[26]ZhangYY,GuJB,WangXS,et al.,2023.Opportunities and challenges: mesenchymal stem cells in the treatment of multiple sclerosis.Int J Neurosci,133(9):1031-1044.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2025 Journal of Zhejiang University-SCIENCE